Results of AIEOP LNH-97 protocol for the treatment of anaplastic large cell lymphoma of childhood

Pediatric Blood and Cancer

Volumn 59, Issue 5, 2012, Pages 828-833

  Pillon, Marta ^a   Gregucci, Fabiana ^a   Lombardi, Alessandra ^b   Santoro, Nicola ^c   Piglione, Matilde ^d   Sala, Alessandra ^e   D'Amore, Emanuele S G ^f   De Santis, Raffaela ^g   Casale, Fiorina ^h   Zecca, Marco ⁱ   Mussolin, Lara ^a   Rosolen, Angelo ^a  

^a UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^b BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^c POLICLINICO   (Italy)

^d REGINA MARGHERITA CHILDREN S HOSPITAL   (Italy)

^e SAN GERARDO HOSPITAL   (Italy)

^f SAN BORTOLO HOSPITAL   (Italy)

^g Unit of Pediatrics   (Italy)

^h SECOND UNIVERSITY OF NAPLES   (Italy)

ⁱ UNIVERSITY OF PAVIA   (Italy)

Author keywords

ALCL; Child; Clinical trials; Non Hodgkin lymphoma; Outcome

Indexed keywords

ACTIVIN RECEPTOR LIKE KINASE 1; CD2 ANTIGEN; CD20 ANTIGEN; CD3 ANTIGEN; CD30 ANTIGEN; CD4 ANTIGEN; CD45RO ANTIGEN; CD5 ANTIGEN; CD56 ANTIGEN; CD57 ANTIGEN; CD7 ANTIGEN; CD79A ANTIGEN; CD8 ANTIGEN; CLUSTERIN; CYTARABINE; GRANZYME B; LACTATE DEHYDROGENASE; LEUKOSIALIN; METHOTREXATE; PERFORIN; PREDNISOLONE;

ADOLESCENT; ARTICLE; BONE MARROW TUMOR; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CAPNOCYTOPHAGA; CAUSE OF DEATH; CENTRAL NERVOUS SYSTEM TUMOR; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; DISEASE COURSE; DRUG PULSE THERAPY; ESCHERICHIA COLI INFECTION; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; GENE REARRANGEMENT; HIGH RISK PATIENT; HUMAN; INFANT; KLEBSIELLA PNEUMONIAE INFECTION; LACTATE DEHYDROGENASE BLOOD LEVEL; LARGE CELL LYMPHOMA; LIVER TOXICITY; LUNG TUMOR; LYMPHOCYTOMA; MALE; MEDIASTINUM TUMOR; MIXED CELL LYMPHOMA; MUCOSA INFLAMMATION; NEUTROPENIA; OVERALL SURVIVAL; POPULATION; PRESCHOOL CHILD; PRIORITY JOURNAL; PSEUDOMONAS INFECTION; SCHOOL CHILD; SECOND LOOK SURGERY; SEPSIS; SHORT COURSE THERAPY; STAPHYLOCOCCUS INFECTION; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR LOCALIZATION;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW NEOPLASMS; CENTRAL NERVOUS SYSTEM NEOPLASMS; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INFANT; INJECTIONS, SPINAL; LYMPHOMA, LARGE-CELL, ANAPLASTIC; MALE; MEDIASTINAL NEOPLASMS; RETROSPECTIVE STUDIES; SKIN NEOPLASMS; SURVIVAL RATE;

EID: 84866165749     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24125     Document Type: Article

References (35)

1. Hochberg J, Waxman IM, Kelly KM, et al. Adolescent non-Hodgkin lymphoma and Hodgkin lymphoma: State of science. Br J Haematol 2008; 144: 24-40.
2. Stein H, Mason DY, Gerdes J, et al. The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: Evidence that Reed-Sternberg cell and histiocytic malignancies are derived from activated lymphoid cell. Blood 1985; 66: 848-858.
3. Stein H, Foss HD, Durkop H, et al. CD30(+) anaplastic large cell lymphoma: A review of its histopathologic, genetic, and clinical features. Blood 2000; 96: 3681-3695.
4. Perkins SL, Pickering D, Lowe EG, et al. Childhood anaplastic large cell lymphoma has a high incidence of ALK gene rearrangement as determined by immunohistochemical staining and fluorescent in situ hybridisation: A genetic and pathological correlation. Br J Haematol 2005; 131: 624-627.
5. Mussolin L, Pillon M, D'Amore ES, et al. Prevalence and clinical implication of bone marrow involvement in pediatric anaplastic large cell lymphoma. Leukemia 2005; 19: 1643-1647.
6. Sandlund JT, Pui C-H, Roberts WM, et al. Clinico-pathological features and treatment outcome of children with large-anaplastic lymphoma and the t(2;5)(p23;q35). Blood 1994; 84: 2467-2471.
7. Brugières L, Le Deley MC, Pacquement H, et al. CD30(+) anaplastic large-cell lymphoma in children: Analysis of 82 patients enrolled in two consecutive studies of the French Society of Pediatric Oncology. Blood 1998; 92: 3591-3598.
8. Seidmann K, Tiemann M, Schrappe M, et al. Short-pulse B-non-Hodgkin lymphoma-type chemotherapy is efficacious treatment for pediatric anaplastic large cell lymphoma: A report of the Berlin-Frankfurt-Munster Group Trial NHL-BFM 90. Blood 2001; 97: 3699-3706.
9. Williams DM, Hobson R, Imeson J, et al. Anaplastic large cell lymphoma in childhood: Analysis of 72 patients treated on the United Kingdom Children's Cancer Study Group chemotherapy regimens. Br J Haematol 2002; 117: 812-820.
10. Laver JH, Kraveka JM, Hutchison RE, et al. Advanced-stage large-cell lymphoma in children and adolescent: Results of a randomized trial incorporating intermediate-dose methotrexate and high-dose cytarabine in the maintenance phase of the APO regimen-A Pediatric Oncology Group phase III trial. J Clin Oncol 2005; 23: 541-547.
11. Rosolen A, Pillon M, Garaventa A, et al. Anaplastic large cell lymphoma treated with a leukemia-like therapy: Report of the Italian Association of Pediatric Hematology and Oncology (AIEOP) LNH-92 Protocol. Cancer 2005; 104: 2133-2140.
12. Lowe EJ, Sposto R, Perkins SL, et al. Intensive chemotherapy for systemic anaplastic large cell lymphoma in children and adolescents: Final results of Children's Cancer Group Study 5941. Pediatr Blood Cancer 2009; 52: 335-339.
13. Le Deley MC, Reiter A, Williams D, et al. Prognostic factors in childhood anaplastic large cell lymphoma: Results of a large European intergroup study. Blood 2008; 111: 1560-1566.
14. Abdulkader I, Cameselle-Teijeiro J, Fraga M, et al. Primary anaplastic large cell lymphoma of the central nervous system. Hum Pathol 1999; 30: 978-981.
15. George DH, Scheithauer BW, Aker FV, et al. Primary anaplastic large cell lymphoma of the central nervous system: Prognostic effect of ALK-1 expression. Am J Surg Pathol 2003; 24: 487-493.
16. Reiter A, Schrappe M, Tiemann M, et al. Successful treatment strategy for Ki-1 anaplastic large-cell lymphoma of childhood: A prospective analysis of 62 patients enrolled in three consecutive Berlin-Frankfurt-Munster group studies. J Clin Oncol 1994; 12: 899-908.
17. Woesmann W, Peters C, Lenhard M, et al. Allogenic haematopoietic stem cell transplantation in relapsed or refractory anaplastic large cell lymphoma of children and adolescents-A Berlin-Frankfurt-Munster group report. Br J Haematol 2006; 133: 176-182.
18. Mori T, Kiyokawa N, Shimada H, et al. Anaplastic large cell lymphoma in Japanese children: Retrospective analysis of 34 patients diagnosed at the National Research Institute for Child Health and Development. Br J Haematol 2003; 121: 94-96.
19. Brugières L, Le Deley MC, Rosolen A, et al. Impact of the methotrexate administration dose on the need for intrathecal treatment in children and adolescents with anaplastic large-cell lymphoma: Results of a randomized trial of the EICNHL Group. J Clin Oncol 2009; 27: 897-903.
20. Le Deley MC, Rosolen A, Williams DM, et al. Vinblastine in children and adolescents with high-risk anaplastic large-cell lymphoma: Results of the randomized ALCL99-vinblastin trial. J Clin Oncol 2010; 28: 3987-3993.
21. Brugières L, Pacquement H, Le Deley MC, et al. Single-drug vinblastine as salvage treatment for refractory or relapsed anaplastic large-cell lymphoma: A report from the French Society of Pediatric Oncology. J Clin Oncol 2009; 27: 5056-5061.
22. Mori T, Takimoto T, Katano N, et al. Recurrent childhood anaplastic large cell lymphoma: A retrospective analysis of registered cases in Japan. Br J Haematol 2006; 132: 594-597.
23. Cesaro S, Pillon M, Visintin G, et al. Unrelated bone marrow transplantation for high-risk anaplastic large cell lymphoma in pediatric patients: A single center case series. Eur J Haematol 2005; 75: 22-26.
24. Gross TG, Hale GA. He W, et al. Hematopoietic stem cell transplantation for refractory or recurrent non-Hodgkin lymphoma in children and adolescents. Biol Blood Marrow Transplant 2010; 16: 223-230.
25. Harris RE, Termuhlen AM, Smith LM, et al. Autologous peripheral blood stem cell transplantation in children with refractory or relapsed lymphoma: Results of children's oncology group study A5962. Biol Blood Marrow Transplant 2011; 17: 249-258.
26. Stansfeld A, Diebold J, Kapanci Y, et al. Updated Kiel classification for lymphomas. Lancet 1998; 1: 292.
27. Harris NL, Jaffe ES, Stein H, et al. A Revised European-American Classification of Lymphoid Neoplasms: A proposal from the International Lymphoma Study Group. Blood 1994; 5: 1361-1392.
28. Murphy SB. Classification, staging and end results of treatment in childhood non Hodgkin's lymphoma: Dissimilarities from lymphomas in adults. Sem Oncol 1980; 7: 332-339.
29. Kaplan EL, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc 1958; 53: 457-481.
30. Peto R, Peto J. Asymptotically efficent rank invariant test procedures. J R Stat Soc A 1972; 135: 185-198.
31. Lamant L, McCarthy K, d'Amore E, et al. Prognostic impact of morphologic and phenotypic features of childhood ALK-positive anaplastic large-cell lymphoma: Results of the ALCL99 study. J Clin Oncol 2011; 29: 4669-4676.
32. Mussolin L, Bonvini P, Ait-Tahar K, et al. Kinetics of humoral response to ALK and its relationship with minimal residual disease in pediatric ALCL. Leukemia 2009; 23: 400-402.
33. Ait-Tahar K, Damm-Welk C, Burkhardt B, et al. Correlation of the autoantibody response to the ALK oncoantigen in pediatric anaplastic lymphoma kinase-positive anaplastic large cell lymphoma with tumor dissemination and relapse risk. Blood 2010; 115: 3314-3319.
34. Katz J, Janik JE, Younes A. Brentuximab Vedotion (SGN-35). Clin Cancer Res 2011; 17: 6428-6436.
35. Gambacorti-Passerini C, Messa C, Pogliani EM. Crizotinib in anaplastic-large cell lymphoma. N Engl J Med 2011; 364: 775-776.